Vonoprazan ทางเลอกใหมในการรกษาโรคทสมพนธกบกรด
Abstract
Acid-related disease is a common, public health problem that interferes with the livelihoods of patients. The most effective and re–commended drugs to inhibit acid secretion in the current guideline are proton pump inhibitors. It is later found to be less effective as well as to have other limitations such as gastric acid-lability, inhibition of H+/K+-ATPase enzyme only in stimulated state, and variable effects in patients with genetic differences. They are also unable to control symptoms during the night. In addition, long-term side effects such as reduction of the absorption of vitamin B12 and magnesium are observed. Therefore, efforts have been made to develop anti-acid secretion drugs to reduce these limitations. The most recent class of acid secretion inhibitors is the potassium competitive acid blocker, vonoprazan. The drug has advantages of rapid and long-acting. It is gastric acid-resistant. Food does not interfere with drug absorption, and drug can control nighttime symptoms. It is thus a new alternative for the treatment of acid-related diseases. However, long term study awaits investigation.
Read the paper
Related studies
- Contribution of social science to large scale biodiversity conservation: A review of research about the Natura 2000 network
- The alignment of agricultural and nature conservation policies in the European Union
- Determination of ecological significance based on geostatistical assessment: a case study from the Slovak Natura 2000 protected area
- Routledge Handbook of the Study of the Commons
- Farmers' acceptance of results-based agri-environmental schemes: A German perspective
- Approaches to Identify the Value of Seminatural Habitats for Conservation Biological Control
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.